Barclays
COCP icon

Barclays’s Cocrystal Pharma COCP Stock Holding History

Barclays’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44 Buy
+42
New +$52 ﹤0.01% 5249
2025
Q4 		– Sell
-16
Closed -$20 – 5308
2025
Q3 		$20 Buy
+16
New +$25 ﹤0.01% 5359
2022
Q1 		– Sell
-13
Closed – – 5034
2021
Q4 		$0 Sell
13
-2,209
-99% -$22.6K ﹤0.01% 4193
2021
Q3 		$28K Buy
2,222
+1,584
+248% +$20.9K ﹤0.01% 4285
2021
Q2 		$10K Sell
638
-737
-54% -$11.2K ﹤0.01% 4625
2021
Q1 		$23K Buy
+1,375
New +$27.9K ﹤0.01% 4343

Other funds holding COCP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Barclays's COCP Position: Q2 2026 in Review

Barclays opened a new position in Cocrystal Pharma (COCP) in Q2 2026: 42 shares worth $44. The stake represents ﹤0.01% of the portfolio and ranks #5249 among its holdings. This is a return to the name: Barclays previously reported a position in COCP as recently as Q3 2025.

Barclays first reported a position in COCP in Q1 2021 and has held it in 6 quarters since. The position peaked at $28K in Q3 2021. 27 funds tracked by Wall St. Rank hold COCP as of Q2 2026.

  • Barclays held 42 shares of Cocrystal Pharma worth $44 as of Q2 2026.
  • Cocrystal Pharma was a new Barclays position in Q2 2026.
  • Cocrystal Pharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5249 holding.
  • Barclays first reported a position in Cocrystal Pharma in Q1 2021 and has held it in 6 quarters since.
  • Barclays's Cocrystal Pharma position peaked at $28K in Q3 2021.
  • 27 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.